21:23 , Feb 26, 2018 |  BC Extra  |  Company News

Achillion rises on positive opinion for C3G therapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday. ACH-4471 is a...
21:41 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Achillion reports preliminary data from a Phase II trial of ACH-4471 for C3 glomerulopathy

Achillion Pharmaceuticals Inc. (NASAQ:ACHN) said preliminary data from the first 2 patients in a Phase IIa trial to treat complement 3 (C3) glomerulopathy (C3G) showed ACH-4471 reduced albumin-to-creatinine ratio from baseline to day 17 by...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue development of JNJ-4178 “in light of...
00:12 , Sep 12, 2017 |  BC Extra  |  Company News

Achillion down after J&J drops HCV compound

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $1.08 (22%) to $3.83 Monday after Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue...
20:07 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

Achillion to begin Phase IIa of ACH-4471 in C3 glomerulopathy

This half, Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) expects to begin a Phase IIa trial of ACH-4471 for 14 days in about 10 patients with low levels of complement 3 (C3) due to C3 glomerulopathy (C3G) or...
22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc.’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4, the advocacy...
15:45 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Achillion reports interim Phase II data for factor D inhibitor in PNH

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) reported interim data from 4 patients with untreated paroxysmal nocturnal hemoglobinuria (PNH) in a Phase II trial showing that oral ACH-4471 led to “meaningful” dose-related improvements in lactate dehydrogenase (LDH) levels,...
00:15 , Aug 10, 2017 |  BC Extra  |  Clinical News

Achillion gains on early factor D inhibitor data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $0.80 (20%) to $4.81 on Wednesday after announcing late Tuesday proof-of-concept data for ACH-4471 to treat paroxysmal nocturnal hemoglobinuria (PNH). Interim data from the first four patients with untreated PNH...
01:06 , Aug 4, 2017 |  BC Extra  |  Politics & Policy

National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the...
23:48 , Apr 10, 2017 |  BC Week In Review  |  Clinical News

ACH-4471: Ph II started

Achillion began an open-label, dose-escalation, New Zealand Phase II trial to evaluate oral ACH-4471 starting at a dose of 100 mg thrice daily in about 4 untreated patients with PNH. Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New...